Literature DB >> 32975278

Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.

Veeral H Ajmera1,2, Edward R Cachay3, Christian B Ramers4, Shirin Bassirian1, Seema Singh1, Richele Bettencourt1, Lisa Richards1, Gavin Hamilton5, Michael Middleton5, Katie Fowler5, Claude Sirlin5, Rohit Loomba1,2,6.   

Abstract

BACKGROUND: Controlled attenuation parameter (CAP) is an ultrasound-based point-of-care method to quantify liver fat; however, the optimal threshold for CAP to detect pathologic liver fat among persons living with human immunodeficiency virus (HIV; PLWH) is unknown. Therefore, we aimed to identify the diagnostic accuracy and optimal threshold of CAP for the detection of liver-fat among PLWH with magnetic resonance imaging proton-density fat fraction (MRI-PDFF) as the reference standard.
METHODS: Patients from a prospective single-center cohort of PLWH at risk for HIV-associated nonalcoholic fatty liver disease (NAFLD) who underwent contemporaneous MRI-PDFF and CAP assessment were included. Subjects with other forms of liver disease including viral hepatitis and excessive alcohol intake were excluded. Receiver operatic characteristic (ROC) curve analysis were performed to identify the optimal threshold for the detection of HIV-associated NAFLD (liver fat ≥ 5%).
RESULTS: Seventy PLWH (90% men) at risk for NAFLD were included. The mean (± standard deviation) age and body mass index were 48.6 (±10.2) years and 30 (± 5.3) kg/m2, respectively. The prevalence of HIV-associated NAFLD (MRI-PDFF ≥ 5%) was 80%. The M and XL probes were used for 56% and 44% of patients, respectively. The area under the ROC curve of CAP for the detection of MRI-PDFF ≥ 5% was 0.82 (0.69-0.95) at the cut-point of 285 dB/m. The positive predictive value of CAP ≥ 285 dB/m was 93.2% in this cohort with sensitivity of 73% and specificity of 78.6%.
CONCLUSIONS: The optimal cut-point of CAP to correctly identify HIV-associated NAFLD was 285 dB/m, is similar to previously published cut-point for primary NAFLD and may be incorporated into routine care to identify patients at risk of HIV-associated NAFLD.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  MRI-PDFF; NASH; steatosis

Mesh:

Year:  2021        PMID: 32975278      PMCID: PMC8204791          DOI: 10.1093/cid/ciaa429

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

1.  Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Authors:  Maud Lemoine; Lambert Assoumou; Stephane De Wit; Pierre-Marie Girard; Marc Antoine Valantin; Christine Katlama; Coca Necsoi; Pauline Campa; Anja D Huefner; Julian Schulze Zur Wiesch; Hayette Rougier; Jean-Philippe Bastard; Hartmut Stocker; Stefan Mauss; Lawrence Serfaty; Vlad Ratziu; Yves Menu; Jerome Schlue; Georg Behrens; Pierre Bedossa; Jacqueline Capeau; Patrick Ingiliz; Dominique Costagliola
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-01       Impact factor: 3.731

Review 2.  The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan.

Authors:  M Sasso; V Miette; L Sandrin; M Beaugrand
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-09-15       Impact factor: 2.947

Review 3.  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018.

Authors: 
Journal:  Diabetes Care       Date:  2018-01       Impact factor: 19.112

4.  Comparison of CT and magnetic resonance mDIXON-Quant sequence in the diagnosis of mild hepatic steatosis.

Authors:  Yong Zhang; Chao Wang; Yangyang Duanmu; Chenxin Zhang; Wei Zhao; Ling Wang; Xiaoguang Cheng; Nicola Veronese; Giuseppe Guglielmi
Journal:  Br J Radiol       Date:  2018-07-20       Impact factor: 3.039

5.  Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.

Authors:  An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Radiology       Date:  2013-02-04       Impact factor: 11.105

Review 6.  Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis.

Authors:  Sumeet K Asrani
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-27       Impact factor: 11.382

Review 7.  Non-invasive evaluation of liver fibrosis using transient elastography.

Authors:  Laurent Castera; Xavier Forns; Alfredo Alberti
Journal:  J Hepatol       Date:  2008-02-26       Impact factor: 25.083

8.  Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease.

Authors:  An Tang; Ajinkya Desai; Gavin Hamilton; Tanya Wolfson; Anthony Gamst; Jessica Lam; Lisa Clark; Jonathan Hooker; Tanya Chavez; Brandon D Ang; Michael S Middleton; Michael Peterson; Rohit Loomba; Claude B Sirlin
Journal:  Radiology       Date:  2014-09-22       Impact factor: 11.105

9.  Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.

Authors:  Cyrielle Caussy; Mosab H Alquiraish; Phirum Nguyen; Carolyn Hernandez; Sandra Cepin; Lynda E Fortney; Veeral Ajmera; Ricki Bettencourt; Summer Collier; Jonathan Hooker; Ethan Sy; Emily Rizo; Lisa Richards; Claude B Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2018-02-19       Impact factor: 17.425

10.  Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Juan Macías; María Mancebo; Dolores Merino; Francisco Téllez; M Luisa Montes-Ramírez; Federico Pulido; Antonio Rivero-Juárez; Miguel Raffo; Montserrat Pérez-Pérez; Nicolás Merchante; Manuel Cotarelo; Juan A Pineda
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

View more
  2 in total

1.  Relationship between controlled attenuated parameter and magnetic resonance imaging-proton density fat fraction for evaluating hepatic steatosis in patients with NAFLD.

Authors:  Ziming An; Qiaohong Liu; Wenli Zeng; Yan Wang; Qian Zhang; Huafu Pei; Xin Xin; Shuohui Yang; Fang Lu; Yu Zhao; Yiyang Hu; Qin Feng
Journal:  Hepatol Commun       Date:  2022-04-05

Review 2.  Imaging biomarkers of NAFLD, NASH, and fibrosis.

Authors:  Veeral Ajmera; Rohit Loomba
Journal:  Mol Metab       Date:  2021-01-15       Impact factor: 7.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.